In a laboratory at Guy's Hospital in London, researchers have grown billions of immune cells from a handful of blood samples—cells that may offer hope to patients with aplastic anemia, a rare and life-threatening blood disorder that leaves the immune system attacking its own bone marrow. The results of a Phase 1 trial, published with results led by Professor Ghulam Mufti of King's College London, mark the first time that autologous regulatory T-cell therapy has been proven safe and effective in humans with this devastating condition.
Aplastic anemia is an autoimmune bone marrow failure disorder in which the patient's own immune system wages war against blood-forming stem cells. The result is dangerously low blood counts and all the complications that follow. Standard treatment relies on powerful immunosuppressive drugs, but these come with considerable side effects and fail to work in up to a third of patients. Those who do respond often relapse and find themselves trapped in long-term dependency on these medications. For many, there has simply been no better option.
The breakthrough rests on a biological insight: patients with aplastic anemia have a critical shortage of regulatory T cells—the immune system's natural brakes. These specialized cells normally suppress harmful autoimmune responses and maintain immune tolerance. When they're depleted or dysfunctional, destructive immune responses against bone marrow stem cells run unchecked. Professors Mufti and Shahram Kordasti theorized that if they could harvest a patient's own Tregs, expand them into billions in a laboratory, and return them to the body, they might restore immune balance.
Six patients with severe or treatment-resistant aplastic anemia were enrolled in the trial by Dr. Shreyans Gandhi, a consultant hematologist at King's College Hospital. The process was meticulous: researchers removed white blood cells containing Tregs from each patient's blood, then Dr. Nazia Mattu and her colleagues at Guy's Hospital's Good Manufacturing Practice laboratory grew billions of these cells in controlled conditions. Two infusions were administered to each patient, two weeks apart.
The trial met its primary goal of safety without a single serious treatment-related adverse event reported. More remarkably, three of the six patients experienced meaningful clinical benefit, becoming independent of red cell or platelet transfusions—a transformation that can profoundly change a patient's quality of life and medical trajectory. Using advanced techniques like mass cytometry, researchers tracked what happened to the infused cells after treatment, discovering they peaked around day 28 and persisted in the bone marrow for at least six months. This persistence matters deeply because it suggests the cells remained long enough to do their therapeutic work.
"This first-in-humans phase 1 trial shows that expanded autologous Tregs are safe to administer and produce favorable clinical responses in patients refractory to standard therapeutic options," Professor Mufti said.
The implications ripple outward. For patients with aplastic anemia who cannot tolerate conventional therapy or have failed to respond to it—particularly elderly patients for whom standard immunosuppressive treatments carry unacceptable risks—this approach offers a potential lifeline. But the impact may extend far beyond this rare blood disorder. The researchers suggest their findings could reshape treatment possibilities for other autoimmune diseases altogether, opening a door to a fundamentally different way of restoring immune balance.